A. van Peer

发表

IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes

Amitava Mitra, Jian Lin, Mai Anh Nguyen, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results

Amitava Mitra, Jian Lin, Mai Anh Nguyen, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

IMI – oral biopharmaceutics tools project – evaluation of bottom‐up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds

Xavier Pepin, Leon Aarons, Hans Lennernäs, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: Where are we now and what are the gaps?

A. Lindahl, A. van Peer, T. Flanagan, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Linearity of Pharmacokinetics and Model Estimation of Sufentanil

D. Stanski, S. Shafer, F. Camu, 1995, Anesthesiology.

Alfentanil kinetics in the elderly

J. Heykants, R. Woestenborghs, A. van Peer, 1984, Clinical pharmacology and therapeutics.

A Combined Specific Target Site Binding and Pharmacokinetic Model to Explore the Non-linear Disposition of Draflazine

M. Danhof, P. Jacqmin, E. Snoeck, 1999, Journal of Pharmacokinetics and Biopharmaceutics.

Excretion and biotransformation of cisapride in dogs and humans after oral administration.

R. Woestenborghs, A. van Peer, J. Hendrickx, 1988, Drug metabolism and disposition: the biological fate of chemicals.

Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates.

Vikash K. Sinha, C. Wassvik, W. Drinkenburg, 2015, Molecular pharmaceutics.

The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.

M. Danhof, A. Dupont, R. Crabbé, 1996, British journal of clinical pharmacology.

Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption.

W. Kirch, A. van Peer, H. Janisch, 1989, Therapeutic drug monitoring.

Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations

M. Danhof, A. Dupont, P. Jacqmin, 1997, European Journal of Clinical Pharmacology.

Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates.

M. Danhof, A. Dupont, L. V. Van Bortel, 1997, British journal of clinical pharmacology.

Pharmacokinetics and tissue distribution of astemizole in the dog

R. Woestenborghs, J. Heykants, A. van Peer, 1986 .

A survey on IVIVC/IVIVR development in the pharmaceutical industry – Past experience and current perspectives

J. Crison, A. Parr, M. Brewster, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia.

J. Heykants, A. van Peer, K. Lehmann, 1988, British journal of anaesthesia.

The use and limitations of deuterated lorcainide in metabolism and pharmacokinetic studies.

R. Woestenborghs, J. Heykants, A. van Peer, 1985, Biomedical mass spectrometry.

Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro–In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound

K. Boussery, K. Allegaert, P. Annaert, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Ketanserin pharmacokinetics in patients with renal failure.

J. G. van der Hoeven, A. van Peer, J. V. van Oene, 1990, British journal of clinical pharmacology.

Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units

J. Decruyenaere, F. Colardyn, K. Vandewoude, 1997, Antimicrobial agents and chemotherapy.

The Pharmacokinetics of Alfentanil After Normothermic and Hypothermic Cardiopulmonary Bypass

C. Doré, D. Macrae, A. van Peer, 1995, Anesthesia and analgesia.

Alfentanil pharmacokinetics in preterm infants.

N. Marlow, J. Heykants, A. van Peer, 1990, Archives of disease in childhood.

Itraconazole pharmacokinetics in patients with renal dysfunction

M. Schurgers, R. Woestenborghs, J. Heykants, 1988, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of oral antifungals and their clinical implications.

R. Woestenborghs, J. Heykants, A. van Peer, 1990, British journal of clinical practice. Supplement.

Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation

J. Donnelly, J. Mouton, A. V. van Vliet, 2006, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease.

T. Donovan, B. Charles, A. van Peer, 1999, British journal of clinical pharmacology.

Modelling and Simulation in the Development and use of Anti-Cancer Agents: An Underused Tool?

France Mentré, Leon Aarons, Amy Racine, 2004, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics of alfentanil during and after a fixed rate infusion.

J. van Egmond, R. Woestenborghs, J. Heykants, 1989, British journal of anaesthesia.

Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data

K. Boussery, P. Colin, K. Allegaert, 2014, Pharmaceutical Research.

Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation

A. Peer, K. Boussery, K. Allegaert, 2015, The AAPS Journal.

Single‐ and multiple‐dose pharmacokinetic studies of tramadol immediate‐release tablets in children and adolescents

A. van Peer, H. Richards, J. Vandenbossche, 2015, Clinical pharmacology in drug development.

Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole.

A. Peer, R. Lefebvre, R. Woestenborghs, 2003, British journal of clinical pharmacology.

The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement

Italo Poggesi, Jan Snoeys, Achiel Van Peer, 2014, Expert opinion on drug metabolism & toxicology.

Dose‐proportionality, bioavailability, and steady‐state kinetics of astemizole in man

R. Woestenborghs, J. Heykants, A. van Peer, 1986 .

Distribution of antipyrine, phenylbutazone and phenytoin in experimental renal failure.

F. Belpaire, M. Bogaert, A. van Peer, 1981, Pharmacology.

Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery

An Vermeulen, Margareta Hammarlund-Udenaes, Vikash K. Sinha, 2014, Pharmaceutical Research.

The pharmacokinetics of risperidone in humans: a summary.

E. Snoeck, G. Mannens, R. Woestenborghs, 1994, The Journal of clinical psychiatry.

In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.

H Lennernäs, A Lindahl, A Van Peer, 2017, Molecular pharmaceutics.

A Model with Separate Hepato-Portal Compartment ("First-Pass" Model): Fitting to Plasma Concentration-Time Profiles in Humans

A. van Peer, V. Piotrovskij, 1997, Pharmaceutical Research.

The metabolism and excretion of galantamine in rats, dogs, and humans.

N. Osselaer, G. Mannens, T. Verhaeghe, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Role of modelling and simulation in Phase I drug development.

L Aarons, M O Karlsson, F Mentré, 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Binding of drugs in serum, blood cells and tissues of rabbits with experimental acute renal failure.

F. Belpaire, M. Bogaert, A. van Peer, 1981, Pharmacology.

Pharmacokinetics of drugs in rabbits with experimental acute renal failure.

F. Belpaire, M. Bogaert, A. van Peer, 1978, Pharmacology.

Variability and impact on design of bioequivalence studies.

A. van Peer, 2010, Basic & Clinical Pharmacology & Toxicology.

Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine.

M. Danhof, A. Dupont, P. Jacqmin, 1998, The Journal of pharmacology and experimental therapeutics.

Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent.

J. Barone, J. Heykants, R. Woestenborghs, 1987, Clinical Pharmacist.

Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study.

H. Van Aken, A. van Peer, H. Noorduin, 1994, Journal of clinical anesthesia.